Vaidya, JS;
Vaidya, UJ;
Baum, M;
Bulsara, M;
Joseph, D;
Tobias, JS;
TARGIT-IORT Global Authors;
(2021)
Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer – better for patients, better for health care systems.
UCL Division of Surgery & Interventional Science: London, UK.
Preview |
Text
Vaidya_Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer – better for patients, better for health for UCL discovery 2022 (1).pdf Download (1MB) | Preview |
Abstract
Introduction: TARGeted Intraoperative radioTherapy (TARGIT-IORT), developed in the late 1990s, delivers radiotherapy targeted to the fresh tumour bed exposed immediately after lumpectomy for breast cancer. Long-term results of the TARGIT-A trial found TARGIT-IORT during lumpectomy to be as effective as whole breast radiotherapy, and led to significantly fewer deaths from non-breast cancer causes. This paper documents its worldwide impact and provides interactive tools for clinicians and patients. / Method: Each centre provided the number of patients treated using TARGIT-IORT. These data were plotted on an interactive ‘My Google Map’. We also created an interactive web-based tool. Using the longterm outcomes from the TARGIT-A trial, we estimated the total savings in travel miles, time, carbon footprint, and the number of deaths from other causes that might be prevented. / Results: Data from 242 (93%) of the 260 centres treating patients from 35 countries were available. The first was treated in 1998 at University College London. As of early 2020, at least 44752 women with breast cancer have been treated with TARGIT-IORT. https://targit.org.uk/travel displays the Google-map of centres with number of cases and the interactive tool that enables patients to find the nearest centre offering TARGIT-IORT and their travel savings. Scaling the main benefits up to the already treated patients, >20 million miles of travel would have been saved, and about 2000 deaths prevented. / Discussion: One can ascertain the number of patients treated with a novel treatment. These data show how widely TARGIT-IORT has now been adopted and gives an indication of its beneficial worldwide impact on a large number of women with breast cancer.
| Type: | Working / discussion paper |
|---|---|
| Title: | Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer – better for patients, better for health care systems |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.14324/000.wp.10121050 |
| Publisher version: | https://doi.org/10.3389/fonc.2022.786515 |
| Language: | English |
| Additional information: | This is a preprint which has not undergone peer review. / This paper has been revised, peer reviewed and published as "Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer—better for patients, better for healthcare systems" in Frontiers in Oncology: https://doi.org/10.3389/fonc.2022.786515 |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci > Department of Targeted Intervention |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10121050 |
Archive Staff Only
 |
View Item |
